Progression to islet destruction in a cyclophosphamide-induced transgenic model - A microarray overview

被引:34
作者
Matos, M
Park, R
Mathis, D
Benoist, C
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Joslin Diabet Ctr,Sect Immunol & Immunogenet, Boston, MA 02115 USA
[2] Harvard Univ, Childrens Hosp, Sch Med, Div Pediat Endocrinol, Boston, MA 02115 USA
关键词
D O I
10.2337/diabetes.53.9.2310
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes appears to progress not as an uncontrolled autoimmune attack on the pancreatic islet beta-cells, but rather in a highly regulated manner. Leukocytic infiltration of the pancreatic islets by autoimmune cells, or insulitis, can persist for long periods of time before the terminal destruction of beta-cells. To gain insight on the final stage of diabetogenesis, we have studied progression to diabetes in a CD4(+) T-cell receptor transgenic variant of the NOD mouse model, in which diabetes can be synchronously induced within days by a single injection of cyclophosphamide. A time-course analysis of the gene expression profiles of purified islets was performed using microarrays. Contrary to expectations, changes in transcripts subsequent to drug treatment did not reflect a perturbation of gene expression in CD4(+) T-cells or a reduction in the expression of genes characteristic of regulatory T-cell populations. Instead, there was a marked decrease in transcripts of genes specific to B-cells, followed by an increase in transcripts of chemokine genes (cxcl1, cxcl5, and ccl7) and of other genes typical of the myelo-monocytic lineages. Interferon-gamma dominated the changes in gene expression to a striking degree, because close to one-half of the induced transcripts issued from interferon-gamma-regulated genes.
引用
收藏
页码:2310 / 2321
页数:12
相关论文
共 42 条
[1]   Checkpoints in the progression of autoimmune disease: Lessons from diabetes models [J].
Andre, I ;
Gonzalez, A ;
Wang, B ;
Katz, J ;
Benoist, C ;
Mathis, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2260-2263
[2]  
André-Schmutz I, 1999, EUR J IMMUNOL, V29, P245, DOI 10.1002/(SICI)1521-4141(199901)29:01<245::AID-IMMU245>3.3.CO
[3]  
2-F
[4]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[5]   Specific reg II gene overexpression in the non-obese diabetic mouse pancreas during active diabetogenesis [J].
Baeza, N ;
Sanchez, D ;
Vialettes, B ;
Figarella, C .
FEBS LETTERS, 1997, 416 (03) :364-368
[6]   Pancreatic regenerating gene overexpression in the nonobese diabetic mouse during active diabetogenesis [J].
Baeza, NJ ;
Moriscot, CI ;
Renaud, WP ;
Okamoto, H ;
Figarella, CG ;
Vialettes, BH .
DIABETES, 1996, 45 (01) :67-70
[7]   The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: Implications for the etiology of autoimmune diabetes [J].
Balasa, B ;
Van Gunst, K ;
Sarvetnick, N .
CLINICAL IMMUNOLOGY, 2000, 95 (02) :93-98
[8]   Genetic control of diabetes progression [J].
Gonzalez, A ;
Katz, JD ;
Mattei, MG ;
Kikutani, H ;
Benoist, C ;
Mathis, D .
IMMUNITY, 1997, 7 (06) :873-883
[9]   Damage control, rather than unresponsiveness, effected by protective DX5+T cells in autoimmune diabetes [J].
Gonzalez, A ;
Andre-Schmutz, I ;
Carnaud, C ;
Mathis, D ;
Benoist, C .
NATURE IMMUNOLOGY, 2001, 2 (12) :1117-1125
[10]   AN IMPROVED METHOD FOR ISOLATION OF MOUSE PANCREATIC-ISLETS [J].
GOTOH, M ;
MAKI, T ;
KIYOIZUMI, T ;
SATOMI, S ;
MONACO, AP .
TRANSPLANTATION, 1985, 40 (04) :437-438